Luke Nordquist, MD, FACP, CEO
drluke@xcancer.comTony Romero, MS, CCRC, Director of Research
tromero@gucancer.comDescription:
This study aims to establish and optimize the trophoblast cell surface antigen 2 (Trop2)-targeted immuno-positron emission tomography/computed tomography (immunoPET/CT) imaging method and its physiological and pathological distribution characteristics, based on which the diagnostic efficacy of the above imaging agents in solid tumors (including uroepithelial cancer, bladder cancer, prostate cancer, lung cancer, nasopharyngeal cancer, liver cancer, cholangiocarcinoma, ovarian cancer, cervical cancer, endometrial cancer, thyroid cancer, head and neck cancer) will be evaluated.
Sponsor:
RenJi Hospital
Phase:
Phase 2/3
Contacts:
Weijun Wei, Ph.D. & M.D. (CONTACT)wwei@shsmu.edu.cn
15000083153
Weijun Wei, Ph.D. & M.D. (PRINCIPAL_INVESTIGATOR) Jianjun Liu, Ph.D. & M.D. (STUDY_CHAIR)Government Study Link:
NCT06851663 - Click here to see study onClinicalTrials.gov
Help us improve your experience